Disclosed are binding agents that include (a) a calcium binding portion which includes an F-helix peptide and a calcium binding loop peptide derived from an EF-hand motif of a calcium binding protein, wherein the C-terminus of the F-helix peptide is covalently linked to the N-terminus of the calcium binding loop peptide by a peptide bond, and (b) a targeting peptide, wherein the N-terminus of the targeting peptide is covalently linked to the C-terminus of the calcium binding portion by a peptide bond. The binding agents can be used for diagnosis and treatment of various disorders.

Biosensors capable of detecting certain biomarkers (e.g., platelet-derived growth factor-BB (PDGF-BB)), as well as methods of fabricating the same and methods of using the same, are provided. The biosensors can be disposable and/or label-free. Electrochemical bipolar exfoliation can be used to exfoliate, reduce, and deposit (in a single step) graphene nanosheets on a desired substrate (e.g., an electrode). Affinity aptamers can be immobilized on the graphene nanosheets disposed on the substrate.

Biosensors capable of detecting certain biomarkers (e.g., platelet-derived growth factor-BB (PDGF-BB)), as well as methods of fabricating the same and methods of using the same, are provided. The biosensors can be disposable and/or label-free. Electrochemical bipolar exfoliation can be used to exfoliate, reduce, and deposit (in a single step) graphene nanosheets on a desired substrate (e.g., an electrode). Affinity aptamers can be immobilized on the graphene nanosheets disposed on the substrate.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Thymic stromal lymphopoietin, Vascular endothelial growth factor receptor 1, CC motif chemokine 1, CC motif chemokine 17, CC motif chemokine 21, CC motif chemokine 27, FLT-3 Ligand, Immunoglobulin G subclass 3, Interleukin-1 receptor type I, Interleukin-20, Interleukin-29, Interleukin-7, Platelet-derived growth factor A/B dimer, Platelet-derived growth factor A/A dimer, and MMP9:TIMP2 complex as diagnostic and prognostic biomarkers in renal injuries.

The present disclosure teaches an assay to determine the likelihood of a successful implantation of an embryo into a female subject leading to a pregnancy. Enabled herein is an improved assisted reproduction technology protocol based on a prognostic evaluation of pregnancy outcomes. Taught herein is a composition comprising reagents required for the prognostic evaluation. Taught herein are assays comprising determination of levels of the biomarkers IL-8, G-CSF and/or VEGFA in a biological fluid sample taken before embryo implantation.

The invention relates to a new method of determining in a sample the presence or absence of one or more analyte members of a group of two or more analytes. The invention therefore relates to a multiplex assay for determining the presence or absence of each analyte in a group of multiple analytes. The assay uses aptamers and transmembrane pores.

Provided in the present invention are adult stem cells derived from human skin dermis, and a method for isolating same. Further provided in the present invention are osteoblastic cells and adipocytes differentiated from the adult stem cells derived from human skin dermis, and a differentiation method therefor. Further provided in the present invention is a composition for osteogenesis or lipogenesis containing the stem cells, osteoblastic cells, or adipocytes. The isolation method of the present invention enables the adult stem cells derived from human skin dermis to be obtained in an easy and simple manner at a high yield rate. Genes and growth factors which are specifically expressed in the adult stem cells derived from human skin dermis isolated using the method can be separated, identified, and used later.

The present invention relates to a method for evaluating a drug involved in angiogenesis. The method includes a drug administration step (A) of administering a drug involved in angiogenesis to a subject having a lesion. The method further includes: an imaging step (1) of performing radiography on a subject in a state where metal nanoparticles are present in a blood vessel or an imaging step (2) of performing fluorescence staining and fluorescence imaging using a dimeric protein; and evaluating the drug using an image acquired in the imaging step (1) or (2).

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Thymic stromal lymphopoietin, Vascular endothelial growth factor receptor 1, C-C motif chemokine 1, C-C motif chemokine 17, C-C motif chemokine 21, C-C motif chemokine 27, FLT-3 Ligand, Immunoglobulin G subclass 3, Interleukin-1 receptor type I, Interleukin-20, Interleukin-29, Interleukin-7, Platelet-derived growth factor A/B dimer, Platelet-derived growth factor A/A dimer, and MMP9:TIMP2 complex as diagnostic and prognostic biomarkers in renal injuries.

The invention relates to a new method of determining in a sample the presence or absence of one or more analyte members of a group of two or more analytes. The invention therefore relates to a multiplex assay for determining the presence or absence of each analyte in a group of multiple analytes. The assay uses aptamers and transmembrane pores.